Amylyx Pharmaceuticals (AMLX) Non Operating Income (2021 - 2026)

Amylyx Pharmaceuticals' Non Operating Income history runs 6 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 844.78% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $4.7 million (up 680.05% YoY), while the FY2024 annual figure was -$1.2 million, down 107.83% from the prior year.
• Non Operating Income was $2.5 million for Q1 2026 at Amylyx Pharmaceuticals, up from $1.1 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $4.5 million in Q4 2023 to a low of -$1.8 million in Q4 2022.
• Historically, Non Operating Income has averaged $798529.4 across 5 years, with a median of $157000.0 in 2024.
• The sharpest annual moves came in 2023 and 2024: Non Operating Income surged 18289.47% in 2023, then tumbled 496.3% in 2024.
• A 5-year view of Non Operating Income shows it stood at -$1.8 million in 2022, then soared by 349.15% to $4.5 million in 2023, then sank by 96.54% to $157000.0 in 2024, then soared by 576.43% to $1.1 million in 2025, then surged by 134.93% to $2.5 million in 2026.
• The last three Non Operating Income figures came in at $2.5 million (Q1 2026), $1.1 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.